Evidence map›Paper›PMID 32582964›Full record

ArticleMolecular medicine reports2020

Statin rosuvastatin inhibits apoptosis of human coronary artery endothelial cells through upregulation of the JAK2/STAT3 signaling pathway.

Kuijing Wang, Bo Li, Yuanyuan Xie, Nan Xia, Minghui Li, Guang Gao

Open access · hybridAbstract read
In one paragraph

Article in Molecular medicine reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Undertreatment or Overtreatment With Statins: Where Are We?Frontiers in cardiovascular medicine · 2022
    Review
  9. Review
  10. Review
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Kuijing WangCadre Ward (Geriatric), The First Hospital of Harbin in Heilongjiang, Harbin, Heilongjiang 150000, P.R. China.
Bo LiDepartment of Cardiology, The First Hospital of Harbin in Heilongjiang, Harbin, Heilongjiang 150000, P.R. China.
Yuanyuan XieCadre Ward (Geriatric), The First Hospital of Harbin in Heilongjiang, Harbin, Heilongjiang 150000, P.R. China.
Nan XiaDepartment of Clinical Laboratory, The First Hospital of Harbin in Heilongjiang, Harbin, Heilongjiang 150000, P.R. China.
Minghui LiCadre Ward (Geriatric), The First Hospital of Harbin in Heilongjiang, Harbin, Heilongjiang 150000, P.R. China.
Guang GaoDepartment of General Surgery, AnZhen Hospital of Beijing, Beijing 100029, P.R. China.
Beijing Anzhen Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The purpose of the present study was to explore the potential molecular signaling pathway mediated by the statin rosuvastatin in cultured human coronary artery endothelial cells (HCAECs) induced by CoCl2. CoCl2 was used to induce the apoptosis of HCAECs. Myocardial infarction rats were established and received statin or PBS treatment. Reverse transcription‑quantitative PCR, western blotting, ELISA, TUNEL assay and immunohistochemistry were used to analyze the role of statin treatment. The results showed that rosuvastatin treatment decreased apoptosis of HCAECs induced by CoCl2 by increasing anti‑apoptosis Bcl‑xl and Bcl‑2 expression, and decreasing pro‑apoptosis Bax, Bad, caspase‑3 and caspase‑9 expression. The myocardial ischemia rat model demonstrated that rosuvastatin treatment decreased the mitochondrial reactive oxygen species, inflammation, mitochondrial damage, lipid catabolism, heart failure and the myocardial infarction areas, but improved the cardiac function indicators, right and left ventricular ejection fraction and increased expression levels of Janus kinase (JAK) and signal transducer and activator of transcription (STAT)3 in myocardial tissue. In conclusion, the results of the current study revealed that the statin rosuvastatin presents cardioprotective effects by activation of the JAK2/STAT3 signaling pathway.

Indexed as

AnimalsApoptosisCell LineCobaltCoronary VesselsDisease Models, AnimalEndothelial CellsGene Expression RegulationHumansMaleMyocardial IschemiaRatsReactive Oxygen SpeciesRosuvastatin CalciumSignal TransductionCobaltcobaltous chlorideReactive Oxygen SpeciesRosuvastatin Calciumapoptosishuman coronary artery endothelial cellsJanus kinase 2myocardial infarctionrosuvastatinsignal transducer and activator of transcription 3statin

Identifiers

PMID32582964
PMCPMC7411340
OpenAlexW3035828358

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.